In India, Breast Cancer Treatment To Become More Affordable

AP Photo/Bikas Das Indian pharmaceutical company Biocon Ltd has announced that it will begin selling a generic version of the breast cancer drug Herceptinto patients in India in February, a move that promises to make breast cancer treatment more accessible in a region where such a diagnosis often spells financial doom. Breast cancer is the second most common form of cancer diagnosis in women living in India. Biocon's new drug, called CANMAb, treats an aggressive form of breast cancer known as HER2-positive. About 150,000 people are diagnosed with breast cancer annually in India, according to Biocon, and 25 percent of that number are of the aggressive HER2-positive form. The new drug is about 25 percent cheaper than similar drugs in the Indian market, according to Indian science publication Biospectrum . While one fifth of all new global breast cancer cases are diagnosed in India, medical treatment remains beyond reach for many patients there. Nearly 45 percent of families with one cancer patient face catastrophic expenditure in India, and about 25 percent are pushed below the poverty line, according to science and medical publisher PLOS . Roche, the company that manufactures Herceptin, decided not to pursue a patent application for its drugin India, paving the way for generic drugmakers to produce cheaper copies, known as biosimilars because they are not identical to the original drug. Global sales for Herceptin were valued at about $6.4 billion in 2012, including about $21 million in India, Biocon said. Read more..

Kids with cancer ring bell, mark end of treatment

The big brass bell that hangs near the nurses' station is rung only by young patients who have finished chemotherapy or radiation. On Jan. 12, Janet Pruneau, of O'Fallon, Ill., got her turn. The St. Louis Post-Dispatch ( ) reports that the 5-year-old was tentative at first but with encouragement from family, friends and hospital staff, she rang the bell six times for each round of chemotherapy she had endured. "I'd like her to ring it 100 times if she wants to," said Kathryn Lenhardt, Janet's grandmother. Doctors found a tumor in the back of Janet's head last spring. Read more..

Inclusion Of Cervical Cancer Treatment In NHIS Lauded

This, the group acknowledge is a positive move since NHIS card bearers suffering from cervical cancer will be confident in seeking treatment and at a very low cost. It is also worth noting that President John Mahama on 25th of September, 2013 revealed in New York when Ghana hosted a side event at the UN General Assembly, in collaboration with the Global Alliance for Vaccines and Immunization (GAVI) and the Global Fund that Ghana will begin a demonstration project vaccinating girls against human papillomavirus (HPV). HPV is the leading cause of cervical cancer, which is the biggest cancer killer of women on the African continent and this vaccination has been carried through as promised. In fact Ghana, was the first GAVI partner country to introduce this vaccine in Africa. Power Over Cervical Cancer(P.O.C.C) Ghana say a very big thank you to the president and urged his administration on to continue coming up with more of such social interventions as well as assist P.O.C.C Ghana in its quest to help win the war against cervical cancer in Ghana. Do you have a story or an article to publish? Please email us to . Read more..